The DIAMOND (Diabetic macular edema patients on a drop program) phase 3 clinical trial results are disappointing but highly informative.
The two pivotal trials evaluated OCS-01 — a topical high-concentration dexamethasone formulation — which failed to meet both its primary visual acuity endpoint and the key secondary endpoint of a 15 letter or greater gain at 52 weeks. While the formulation demonstrated meaningful and persistent reductions in retinal thickness on OCT, the absence of a corresponding visual benefit reinforces a lesson that retina specialists have learned repeatedly in the management of diabetic macular edema: Anatomic improvement alone does not necessarily translate into better vision.
The results also highlight the challenge of delivering therapeutically meaningful intravitreal and macular drug levels through topical administration externally. Although the concept of a noninvasive DME treatment remains attractive, OCS-01 does not currently appear poised to replace injections or steroid implants for the management of this condition. Future innovation will likely continue to focus on durability, sustained delivery and earlier intervention strategies rather than topical therapy alone. Clinically, these data are unlikely to alter the current treatment paradigm, which remains centered on the continued use of intravitreal anti-VEGF agents such as aflibercept formulations and faricimab, with steroid implants reserved for second-line therapy.
